Biogen

In October 2022, we reported that Biogen was seeking a preliminary injunction in its BPCIA case brought in the District of Delaware against Sandoz relating to Sandoz’s proposed multiple sclerosis biosimilar of TYSABRI (natalizumab). The parties completed their briefing on Biogen’s motion in April, and Judge Williams has scheduled a hearing for May 17 at…

Biogen (BIIB) announced Wednesday that the European Commission has extended the regulatory market protection for its multiple sclerosis therapy until 2025. Read more here.

Biogen has set a price for its recently approved ALS therapy Qalsody (tofersen) at $14,230 per dose. Read more here.

Long known as a neuroscience company, Biogen “could migrate” into immunology, CEO Christopher Viehbacher signaled Tuesday. | Long known as a neuroscience company, Biogen “could migrate” into immunology, CEO Christopher Viehbacher signaled Tuesday.

Biogen’s new CEO Christopher Viehbacher has wasted no time getting a pi | Biogen’s new CEO Christopher Viehbacher has wasted no time getting a pipeline re-prioritization underway while signaling that the formerly restrained company is ready to make some deals.

Fake LinkedIn executive profiles are creating an issue for the business networking site, a report from KrebsOnSecurity said. The fake identities, pairing AI-generated profile photos with text from legitimate accounts, have made for trouble for corporate HR departments, and those which work with invite-only groups on LinkedIn. KrebsOnSecurity has looked into numerous fake profiles, which…